PRKDC and neoplasm: The in vivo anticancer efficacy of RANCE‐1 was determined in xenograft Caki‐1 tumor bearing NOD.CB17‐Prkdc SCID/J mice following ip administration of seven doses spaced by 72h followed by a 72h recovery period before sacrifice.